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ABSTRACT 
Background: A new herbal drug setarud (IMODTM) containing selenium, carotene, and 
flavonoids, was expected to have positive effects on lipid metabolism and liver functions, 
due to the nature of its primary components. This study was designed to determine 
effectiveness of the drug in reducing the risk of development of diet-induced 
hypercholesterolemia in laboratory animals.  
Methods: Two groups of male rabbits (n=10 per group) as: intact and control groups on 
regular chow, were fed a high-cholesterol diet, and two experimental groups were 
maintained on the same diet and treated with different daily doses (0.02 g/kg and 0.04 g/kg) 
of setarud (brand name IMOD®, Pars Roos, Iran). The treatment groups were then 
compared with the intact and control groups and with one another for the effects of the drug 
which was determined by changes in blood sugar, serum lipid levels, and liver function 
tests.  
Results: Results showed that drug had important benefits in alleviating the impact of high-
cholesterol diet on serum lipids and liver function markers in drug-treated groups relative to 
hyperlipidemic controls (p < 0.001). A more favorable modification of total cholesterol and 
triglyceride levels and the atherogenic index was found in animals, which received 0.04 
g/kg drug, as compared to the 0.02 g/kg dose group (p < 0.05). Assessment of serum total 
protein, albumin, transaminases, and bilirubin levels showed that no changes in liver 
function of control and drug-treated animals during the period of the study.  
Conclusion: From the results of this study it may concluded that setarud has dose-
dependent positive effects on liver and lipid metabolism and may acts as an effective anti-
hyperglycemic agent. 
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INTRODUCTION 
The drugs that are currently in use to treat 
hypercholesterolemia, including HMG-CoA 
reductase inhibiting agents (statins) are generally 
well tolerated but can cause dose-dependent 
adverse reactions, especially in patients suffering 
from chronic disease complications (1). In view of 
the growing recognition of the potential role of 
the selenium (Se), as an essential micronutrient in 
metabolism, some selenium compounds have 
been effective for the treatment of hyper-
cholesterolemia and cardiovascular disease (2,3). 
Selenium is involved in the metabolism of lipids, 
carbohydrates and proteins and protects cells from 
oxidative stress (2-4). Some illnesses such as 
cardiovascular disorders, immune deficiency, and 
cancer have been linked to dietary Se deficiency. 
A low serum Se concentration has been reported 
to reduce liver microsomal enzymes activity and 
lower high density lipoprotein cholesterol (HDL) 
level in animals (5). Dietary supplementations of 
Se have resulted in higher hepatic concentrations 
of reduced glutathione (6,7), a potent intracellular 
inhibitor of lipid peroxidation, and decrease in the 
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plasma total cholesterol (TC), very low density 
lipoprotein (VLDL) and low density lipoprotein 
(LDL) levels (8). 
Protective action of dietary Se against high-fat 
diet induced hypercholesterolemia in animals 
have previously been documented (9,10). Other 
nutrients like polyphenolic flavonoids and 
pigmented carotenoids have also been reported to 
have potent hypolipidemic and hypoglycemic 
effects in animals (11,12).  
In the search for new medicines with the capacity 
to correct nutritional deficiencies and to treat 
immune disorders, the drug namely setarud 
containing Se, carotene, and flavonoids was 
designed. According to the nature of its primary 
ingredients, the formulation may have positive 
effects on liver and lipid metabolism. This study 
was performed to determine the effectiveness of 
the drug against diet-induced hyper-
cholesterolemia and liver metabolism changes in 
animals.  
 
MATERIALS AND METHODS 
 
Experimental Animals and Diets 
This preclinical study was conducted at Pasteur 
Institute of Iran, Tehran. Forty male New Zealand 
White rabbits, with a mean age of 3.5 months and 
average weight of 2000 g, were selected for 
experiments. Animals were handled in accord 
with the guideline of the laboratory animal 
welfare (13). The selected rabbits were housed 
individually in aluminium cages and kept in a 
room maintained at 20-22°C with a 12 hrs 
light/dark cycle. The animals were fed with 
standard laboratory rabbit food (Behparvar, 
Iran). Food and water were given ad libitum 
during the entire one-month period of the study. 
The animals were randomized equally (n=10 per 
group) into four groups: (1) intact, which were fed 
a standard chow supplemented with 2 ml/kg of 
sunflower oil daily by a nasogastric (NG) tube; 
(2) control fed via NG tube a 
hypercholesterolemic diet (0.5 g/kg body 
mass/day): of 5% cholesterol, plus 1% cholic acid, 
0.5% thiouracil – designed as CCT diet (14); and 
two treatment groups given by NG tube CCT diet 
along with 0.02 (3) or 0.04 (4)  g/kg body 
mass/day setarud (IMOD®, Pars Roos Co., 
Tehran, Iran) during subsequent 30 days. The 
doses were selected based on the results of the 




Blood samples were collected from the marginal 
left ear veins of 12-hrs fasting animals. 
Laboratory tests, including serum cholesterol 
lipids, triglyceride, total protein, albumin, blood 
sugar, bilirubin, transaminases and alkaline 
phosphatase (ALP), were carried out, using 
commercial kits (Bayer Diagnostics GmbH, 
Munich, Germany).  
 
Data analysis 
Results are expressed as means ± SEM (n=3). 
Data were analyzed by SPSS software 13.0 (SPSS 
Inc., Chicago, IL, USA). One-way ANOVA was 
used to compare mean values among the groups. 
Post-hoc multiple comparison tests (Bonferroni 
method) were carried out. p values <0.05 were 
considered significant.  
 
RESULTS 
All animals survived during the study. 
Hypercholesterolemia was induced in control 
cholesterol-fed group as proved by the results of 
biochemical tests (Table 1). Analysis of the 
changes of serum lipid levels in this group 
showed two times increase in total cholesterol 
(TC) and triglycerides and about three times 
elevation in VLDL, LDL and atherogenic index 
(TC–HDL/HDL) compared to those of intact 
group (p < 0.01).  
In animals treated with 0.02 g/kg of setarud, total 
cholesterol, triglyceride, VLDL-C and LDL levels 
were lowered by 36.6%, 22.6%, 33.7%, 41.3%, 
respectively, while HDL level was higher by 
11.2% in comparison with corresponding values 
of the control group. As a result, the atherogenic 
index was reduced by 63.4% in the group which 
received a dose of 0.02 g/kg. A more pronounced 
decrease in atherogenic lipid fractions compared 
to controls was registered in the serum of the 
animals, which received 0.04 g/kg drug as related 
to the 0.02 g/kg group: total cholesterol by 48.0% 
vs. 36.6%, triglyceride by 39.1% vs. 22.6%, and 
atherogenic index by 70.4% vs. 63.4% (p < 0.01), 
respectively. 
Liver function tests in control cholesterol-fed 
animals displayed a mild to moderate increase in 
serum total protein (13.3%), albumin (11.1%), 
total bilirubin (64.5%), and blood sugar (40.0%) 
levels in comparison with intact rabbits (Table 2), 
while in drug groups, all records were at intact 
level (p > 0.05).  
Serum levels of alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), and ALP were 
significantly augmented in control animals 
compared to the corresponding values of the intact 
group (Table 3). However, in animals treated with 
0.02 g/kg of setarud, serum ALT level was 
lowered by 18.6%, AST was lowered by 15.4%, 
and ALP was lowered by 17.7% compared to 
controls (p < 0.05). Furthermore, the 0.04 g/kg 
group showed minimal alterations in liver 
function tests, with the activity of ALT, AST and 
ALP being closer to that of intact rabbits when 
compared to the 0.02 g/kg group (p < 0.05). 
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Table 1. Protective effects of setarud (IMODTM) against diet-induced hyperlipidemia in rabbits 











Intact 2.61±0.74 1.62±0.04 0.40±0.006 0.33±0.01 0.61±1.21 0.61±0.004 
Control 6.31±0.47** 2.00±0.04* 1.21±0.004** 1.01±0.03** 1.15±0.04** 2.16±0.010** 
Setarud 0.02 g/kg 4.00± 0.37## 2.24±0.01# 0.71±0.001## 0.67±0.01## 0.89±0.03## 0.79±0.042## 
Setarud 0.04 g/kg 3.28±0.04## 2.00±0.04 0.70±0.004## 0.60±0.01## 0.70±0.03## 0.64±0.001## 
Each value is represented as mean ±SEM; *p < 0.05, **p < 0.01 compared to intact group; #p < 0.05, ##p < 0.01 compared to control 




Table 2. Influence of setarud on changes (IMODTM) in biochemical tests in rabbits on CCT diet 









Intact 6.0±0.60 54.0±6.1 5.0±0.4   7.05±2.6 1.40±0.36 
Control 6.8±0.66** 60.0±4.6** 7.0±0.4** 11.60±1.7** 4.72±0.18** 
Setarud, 0.02 g/kg 6.1±0.13# 56.6±2.1# 5.0±0.1##   7.44±1.1## 1.99±0.01## 
Setarud, 0.04 g/kg 6.0±0.17## 56.0±1.6## 5.1±0.1##   7.05±1.6## 1.90±0.13## 




Table 3. Effects of setarud (IMODTM)on liver enzymes activity in rabbits on CCT diet 





intact 56.6 ± 1.14 80.4 ± 1.11 501.6 ± 16.6 
control 79.0 ± 2.14** 118.6 ± 1.17**     700.0± 23.1** 
setarud, 0.02 g/kg 64.3 ± 3.40## 100.3± 3.60#    576.0± 11.1# 
setarud, 0.04 g/kg 61.5 ± 5.20##   90.4 ± 5.20##     540.0± 11.1## 
Each value is represented as mean ±SEM; **p < 0.01 compared to intact group; #p < 0.05, ##p < 0.05 compared to control group. 
ALT=alanine aminotransferase, AST=aspartate aminotransferase, ALP=alkaline phosphatase. 
 
DISCUSSION 
Results of this study show that setarud, a 
combination of Se, carotenoids and flavonoids, 
hinder development of hyperlipidemia in rabbits 
by stabilizing both blood sugar and serum 
cholesterol and triglyceride levels. In the previous 
studies it has been reported that, Se 
supplementation led to a major decrease in plasma 
concentrations of LDL, VLDL, total cholesterol, 
and triglycerides both in human (15) and animals 
(8,16,17). Thus, it may be assumed that Se present 
in the drug was responsible for a large part of the 
observed effects.  
Selenium, when supplied exogenously, inhibited 
both high-fat and alcohol-induced hyperlipidemia 
in animals that is consistent with data of this study 
(9,10,18). This suppression was due to decrease in 
lipid synthesis as evidenced by the lower activity 
of HMG-CoA reductase in liver microsomes. In 
contrast, elevated cholesterol in rats with Se 
deficiency was related to the increase in HMG-
CoA reductase activity (19). Selenium intake may 
lower plasma cholesterol concentration or 
stabilize it at low levels via its key role in 
metabolism of thyroid hormones (20), which are 
among the most potent agents known to reduce 
plasma LDL concentrations. Selenium is a critical 
element of selenoenzyme, type I iodothyronine 
deiodinase (5'-DI), which is required for hepatic 
conversion of T4 to 3,3,5-tri-iodothyrosine (T3) 
and also takes part in regulation of apolipoprotein 
B (apo B) expression. Thus, Se deficiency may 
cause an inhibition of 5'-DI activity, leading to a 
reduction in T3 level and related decrease in LDL-
cholesterol elimination from blood through down 
regulation of LDL receptor activity by reduction 
of LDL receptor mRNA expression. Selenium 
supplementation may lead to a decrease in apo B 
expression through increase in LDL receptor 
mRNA level by modulation of 5'-DI expression 
which, in turn, may have the protective role 
against hypercholesterolemia (21,22). In addition, 
Se is a main component of glutathione peroxidase 
protecting tissues against free radicals (6-8). 
Therefore, some beneficial effects of setarud, 
namely normalizing the levels of liver enzymes 
which were observed in experimental groups, may 
be due to Se antioxidant activity in liver cells, 
although the exact mechanisms of its effects are 
not well understood. 
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Setarud has been especially formulated with 
extracts of Rosa sp., Urtica dioica and Tanacetum 
vulgare, and Se (23). Beside of Se, other 
substances present in setarud, such as carotene 
and flavonol quercetin (unpublished data), might 
account for anti-atherogenic and anti-glycemic 
action of the drug. Both carotene and quercetin 
have been reported to be effective in impeding the 
increase in serum cholesterol and glucose (11,12, 
24). The protective activity of the drug was 
considerable in the 4-week study with more 
favorable effects in animals, which received 
higher drug dosage. The combination of all above 
nutrients in setarud turns out to be not less 
effective than individual supplements, i.e, Se, 
carotene or flavonol, in counteracting the 
cholesterolemia and hyperglycemia.  
According to its ingredients and dose-dependent 
profoundly positive effects on liver and lipid and 
sugar metabolism, setarud, branded as IMOD, was 
active as an anti-hyperlipidemic and anti-
hyperglycemic agent and the composition may be 
useful as nutritional support for detoxification and 
improvement of liver functions. The wide range 
of its influence on liver functions and levels of 
serum cholesterol and sugar suggest to study the 
prospective use of setarud in healthy patients.   
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